These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10463719)

  • 1. Are surrogate markers adequate to assess cardiovascular disease drugs?
    Temple R
    JAMA; 1999 Aug; 282(8):790-5. PubMed ID: 10463719
    [No Abstract]   [Full Text] [Related]  

  • 2. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.
    Psaty BM; Weiss NS; Furberg CD; Koepsell TD; Siscovick DS; Rosendaal FR; Smith NL; Heckbert SR; Kaplan RC; Lin D; Fleming TR; Wagner EH
    JAMA; 1999 Aug; 282(8):786-90. PubMed ID: 10463718
    [No Abstract]   [Full Text] [Related]  

  • 3. Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials.
    Whyte J; Woodcock J; Wang J
    JAMA Intern Med; 2017 May; 177(5):724-727. PubMed ID: 28288256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges.
    Heinonen TM; Aamer M; Marshall C; Black DM; Tardif JC
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):989-94. PubMed ID: 23030288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.
    Vaduganathan M; Butler J; Gheorghiade M
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27707750
    [No Abstract]   [Full Text] [Related]  

  • 6. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
    Temple R
    Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium.
    Sager PT; Seltzer J; Turner JR; Anderson JL; Hiatt WR; Kowey P; Prochaska JJ; Stockbridge N; White WB
    Am Heart J; 2015 Apr; 169(4):486-95. PubMed ID: 25819855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conducting pediatric cardiovascular trials. Introduction.
    Sanders SP
    Am Heart J; 2001 Aug; 142(2):218-23. PubMed ID: 11479457
    [No Abstract]   [Full Text] [Related]  

  • 9. Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020.
    Chen S; Li J
    JAMA Netw Open; 2021 Mar; 4(3):e212640. PubMed ID: 33755163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
    Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
    Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
    Roden DM; Temple R
    Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
    [No Abstract]   [Full Text] [Related]  

  • 12. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 13. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.
    Psaty BM; Lumley T
    JAMA; 2008 Mar; 299(12):1474-6. PubMed ID: 18364491
    [No Abstract]   [Full Text] [Related]  

  • 14. Biomarkers and surrogate markers: an FDA perspective.
    Katz R
    NeuroRx; 2004 Apr; 1(2):189-95. PubMed ID: 15717019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.
    Wallach JD; Ciani O; Pease AM; Gonsalves GS; Krumholz HM; Taylor RS; Ross JS
    BMC Med; 2018 Mar; 16(1):45. PubMed ID: 29562926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.
    Knopf K; Baum M; Shimp WS; Bennett CL; Faith D; Fishman ML; Hrushesky WJ
    BMJ; 2016 Dec; 355():i6286. PubMed ID: 28039123
    [No Abstract]   [Full Text] [Related]  

  • 17. Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.
    Mitka M
    JAMA; 2010 Jan; 303(3):211-2. PubMed ID: 20085945
    [No Abstract]   [Full Text] [Related]  

  • 18. An analysis of FDA-approved drugs for cardiovascular diseases.
    Kinch MS; Surovtseva Y; Hoyer D
    Drug Discov Today; 2016 Jan; 21(1):1-4. PubMed ID: 25218930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.
    Shahid I; Khan MS; Sohail A; Khan SU; Greene SJ; Fudim M; Michos ED
    JAMA Netw Open; 2022 Feb; 5(2):e220035. PubMed ID: 35212753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.